Alphatec (NASDAQ:ATEC) Major Shareholder Squadron Capital Llc Sells 28,834 Shares

by · The Cerbat Gem

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) major shareholder Squadron Capital Llc sold 28,834 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $21.03, for a total transaction of $606,379.02. Following the completion of the sale, the insider directly owned 10,645,045 shares of the company’s stock, valued at approximately $223,865,296.35. This represents a 0.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Squadron Capital Llc also recently made the following trade(s):

  • On Monday, December 8th, Squadron Capital Llc sold 221,166 shares of Alphatec stock. The shares were sold at an average price of $21.20, for a total value of $4,688,719.20.
  • On Monday, November 24th, Squadron Capital Llc sold 250,000 shares of Alphatec stock. The shares were sold at an average price of $20.62, for a total value of $5,155,000.00.
  • On Wednesday, November 12th, Squadron Capital Llc sold 250,000 shares of Alphatec stock. The shares were sold at an average price of $20.80, for a total transaction of $5,200,000.00.

Alphatec Price Performance

Shares of ATEC traded up $0.23 during mid-day trading on Wednesday, hitting $20.90. The company’s stock had a trading volume of 3,368,927 shares, compared to its average volume of 2,125,982. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24. The firm has a 50-day moving average price of $18.04 and a 200 day moving average price of $14.95. Alphatec Holdings, Inc. has a fifty-two week low of $8.69 and a fifty-two week high of $22.66. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -20.10 and a beta of 1.08.

Alphatec (NASDAQ:ATEC – Get Free Report) last released its earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.28) earnings per share. On average, research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ATEC shares. Loop Capital set a $25.00 price target on Alphatec in a research note on Wednesday. Canaccord Genuity Group raised their target price on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Needham & Company LLC raised their price objective on Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a report on Monday. Finally, Morgan Stanley set a $23.00 target price on shares of Alphatec in a research note on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.

Read Our Latest Stock Report on Alphatec

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Nuveen LLC bought a new stake in Alphatec in the first quarter worth $135,874,000. Vanguard Group Inc. boosted its position in Alphatec by 2.4% during the third quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock worth $99,091,000 after purchasing an additional 158,295 shares during the period. American Century Companies Inc. grew its holdings in Alphatec by 2.6% during the third quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company’s stock valued at $92,133,000 after purchasing an additional 159,330 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Alphatec by 10.8% in the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock worth $35,773,000 after buying an additional 342,656 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Alphatec by 7.4% in the second quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company’s stock worth $29,946,000 after buying an additional 185,297 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Read More